Compare EAD & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EAD | SRPT |
|---|---|---|
| Founded | 2003 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.8M | 2.3B |
| IPO Year | N/A | 1997 |
| Metric | EAD | SRPT |
|---|---|---|
| Price | $6.77 | $21.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $26.23 |
| AVG Volume (30 Days) | 178.9K | ★ 3.4M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,413,715,000.00 |
| Revenue This Year | N/A | $13.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.15 |
| 52 Week Low | $5.69 | $10.42 |
| 52 Week High | $6.81 | $129.84 |
| Indicator | EAD | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 52.13 |
| Support Level | $6.76 | $20.93 |
| Resistance Level | $6.80 | $22.97 |
| Average True Range (ATR) | 0.04 | 1.22 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 0.00 | 51.65 |
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.